Full Press Release Details
4D Molecular Therapeutics Announces Presentation of Preclinical Data at the 6th International Update on Fabry Disease and Provides Clinical Update.
FDMT
4D Molecular Therapeutics Announces Presentation of Preclinical Data at the 6th International Update on Fabry Disease and Provides Clinical Update
Key Takeaway: 4D Molecular Therapeutics Announces Presentation of Preclinical Data at the 6th International Update on Fabry Disease and Provides Clinical Update
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration